Welcome to our dedicated page for Trevi Therapeutics news (Ticker: TRVI), a resource for investors and traders seeking the latest updates and insights on Trevi Therapeutics stock.
Trevi Therapeutics, Inc. reports news on its clinical-stage biopharmaceutical development of Haduvio, an oral extended-release formulation of nalbuphine, for chronic cough in patients with idiopathic pulmonary fibrosis, non-IPF interstitial lung disease, and refractory chronic cough. Company updates commonly cover clinical trial results and plans, FDA interactions, medical-conference presentations, intellectual property, and the investigational status of Haduvio.
Trevi also reports financing and corporate updates tied to its development strategy, including common stock offerings, quarterly financial results, cash runway commentary, and participation in healthcare investor events.
Trevi Therapeutics (NASDAQ: TRVI), a clinical-stage biopharmaceutical company developing Haduvio™ (oral nalbuphine ER) for chronic cough treatments, announced its participation in three major conferences in June 2025. The company will present at the American Cough Conference (June 6-7) discussing RIVER trial demographics for refractory chronic cough. At the CPDD 87th Annual Scientific Meeting (June 14-18), they will present research on nalbuphine's human abuse potential. Finally, at the BIO International Convention (June 16-19), the company will deliver a corporate presentation. Key executives, including CEO Jennifer Good and other senior management, will represent Trevi at these events.
Trevi Therapeutics (NASDAQ: TRVI) has scheduled its Q1 2025 financial results and corporate update conference call for May 8, 2025, at 4:30 p.m. ET. The company, which is developing Haduvio™ (oral nalbuphine ER) for chronic cough treatment in patients with idiopathic pulmonary fibrosis (IPF) or refractory chronic cough (RCC), will host the event via conference call and live audio webcast. Investors can join by dialing (877) 870 4263 (domestic) or (412) 317 0790 (international). The webcast will be available through the 'Investors & News' section on Trevi's website and archived for 30 days afterward.
Trevi Therapeutics (Nasdaq: TRVI), developing Haduvio™ (oral nalbuphine ER) for chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), has announced its participation in three major investor conferences this April 2025.
The company will present at the following events:
- 24th Annual Needham Virtual Healthcare Conference (April 7-10) with a corporate presentation on April 7 at 11:00-11:40 a.m. ET
- Jones Healthcare and Technology Innovation Conference (April 8-9) in Las Vegas, with a presentation on April 9 at 11:00-11:20 a.m. PT
- Piper Sandler Spring Biopharma Symposium (April 16-17) in Boston
Trevi Therapeutics (NASDAQ: TRVI) reported significant progress in its clinical trials for Haduvio, a therapy for chronic cough conditions. The company announced positive topline data from Phase 2a RIVER trial showing a 57% placebo-adjusted reduction in 24-hour cough frequency for refractory chronic cough patients.
Key developments include completed enrollment in the Phase 2b CORAL trial for IPF chronic cough patients, with topline data expected in Q2 2025, and positive sample size re-estimation outcome requiring no changes to the study. The company also reported positive results from its Human Abuse Potential study.
Financial highlights for Q4 2024:
- Cash position: $107.6 million, with runway into H2 2026
- R&D expenses: $9.3 million (up from $6.5M in Q4 2023)
- Net loss: $11.4 million (compared to $7.8M in Q4 2023)
Trevi Therapeutics (NASDAQ: TRVI) has scheduled its fourth quarter and year-end 2024 financial results announcement and corporate update for March 18, 2025, at 4:30 p.m. ET. The company, which is developing Haduvio™ (oral nalbuphine ER) for chronic cough treatment in patients with idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), will host a conference call and live audio webcast.
Participants can join via phone at (877) 870 4263 (domestic) or (412) 317 0790 (international). The webcast will be available through the 'Investors & News' section on Trevi's website, with a 30-day replay option available after the event.
Trevi Therapeutics (NASDAQ: TRVI) announced positive topline results from its Phase 2a RIVER trial evaluating Haduvio for refractory chronic cough (RCC). The trial met its primary endpoint with a 57% placebo-adjusted reduction in 24-hour cough frequency (p0.0001).Key findings include:
- 67% reduction in cough frequency from baseline
- 66% reduction in severe cough subgroup
- 68% reduction in moderate cough subgroup
- 84% of Haduvio patients achieved at least 30% reduction in cough frequency vs 29% for placebo
The trial involved 66 patients in a randomized, double-blind, placebo-controlled crossover study. Significant improvements were observed as early as Day 7 at the lowest dose (27mg BID). Common side effects included constipation, nausea, somnolence, headache, dizziness, and fatigue, with no serious adverse events reported.